Breast Cancer

A recent study showed that menopausal hormone therapy or vaginal estrogen therapy did not increase the risk for breast cancer recurrence among postmenopausal women with early-stage, ER-positive disease.

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with HER2-low breast cancer.

During the early months of the COVID-19 pandemic, the number of cancer screenings in the U.S. dropped sharply as states imposed stay-at-home orders and health care providers sought to reduce exposure to the virus and redeployed personnel.

Healio spoke with Fumiko Chino, MD, radiation oncologist at Memorial Sloan Kettering Cancer Center and winner of the Healio Patient Voice award, about the cost of cancer care and how it impacts treatment.

The addition of pembrolizumab to first-line chemotherapy significantly prolonged OS compared with chemotherapy alone among a subgroup of patients with inoperable or metastatic triple-negative breast cancer, according to study results.

Menopausal hormone therapy or vaginal estrogen therapy did not appear associated with increased risk for breast cancer recurrence or mortality among postmenopausal women with early-stage, ER-positive disease, according to study results.

Updated data from a randomized phase 3 study showed a pertuzumab-based regimen continued to provide durable benefit for people with HER2-positive early breast cancer, according to the agent’s manufacturer.

Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, according to an updated position statement from the North American Menopause Society.

In a recent survey of oncologists, 80% of women and 56% of men said they experienced sexual harassment in the past year.

Physicians may overlook substantial symptoms in certain patients undergoing radiotherapy for breast cancer, especially those who are young, Black or of “other” race or ethnicity, according to a study published in JAMA Oncology.